MARKET

NSPR

NSPR

INSPIREMD
AMEX

Real-time Quotes | Nasdaq Last Sale

0.7850
-0.0527
-6.29%
After Hours: 0.7800 -0.005 -0.64% 17:25 03/03 EST
OPEN
0.8400
PREV CLOSE
0.8377
HIGH
0.8500
LOW
0.7530
VOLUME
8.76M
TURNOVER
--
52 WEEK HIGH
1.480
52 WEEK LOW
0.2820
MARKET CAP
87.29M
P/E (TTM)
-0.6239
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
InspireMD Granted US Patent Titled 'Stent assembly and methods for treatment via body lumens'
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=10932926.PN.&OS=PN/10932926&RS=PN/10932926
Benzinga · 1d ago
InspireMD to Report Fourth Quarter and Year-End 2020 Financial Results on Tuesday, March 9, 2021 and Provide Corporate Update
InspireMD, Inc. (NYSE American: NSPR) ("InspireMD" or the "Company"), the developer of the CGuard(TM) Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announces it will report fiscal fourth quarter ...
GlobeNewswire · 1d ago
5 Penny Stocks To Buy With Up To 219% Upside According To Analysts
Feb 24, 2021 (Penny Stocks via COMTEX) -- Are Analysts Right About These Penny Stocks To Buy? Who's ready for another busy week with penny stocks? I know...
Penny Stocks · 02/24 21:12
BRIEF-InspireMD Engages Hart Clinical Consultants To Conduct Clinical Trial For Cguard Carotid Stent System In The U.S.
reuters.com · 02/24 11:17
InspireMD Says Has Engaged Hart Clinical Consultants To Conduct A Clinical Trial Of CGuard Carotid Stent System In The US
TEL AVIV, Israel, Feb. 24, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE:NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced
Benzinga · 02/24 11:09
InspireMD Engages Hart Clinical Consultants to Conduct Clinical Trial for CGuard Carotid Stent System in the United States
GlobeNewswire · 02/24 11:00
Open Surgery Heart Valves Market Share Analysis, Key Growth Drivers, Challenges, Leading Key Players Review, Demand and Upcoming Trend by Forecast to 2026
Feb 17, 2021 (The Expresswire) -- The report provides revenue of the globalOpen Surgery Heart Valves Market for the period 2016 and 2026, considering 2020 as...
The Express Wire · 02/17 05:51
Insider Trends: InspireMD Insider Buy Reducing 90-Days of Sells
MT Newswires · 02/10 07:28
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NSPR. Analyze the recent business situations of INSPIREMD through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NSPR stock price target is 0.8500 with a high estimate of 1.000 and a low estimate of 0.7000.
EPS
Institutional Holdings
Institutions: 6
Institutional Holdings: 43.69K
% Owned: 0.04%
Shares Outstanding: 111.19M
TypeInstitutionsShares
Increased
0
0
New
3
38.75K
Decreased
2
245.19K
Sold Out
5
256.10K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-2.50%
Healthcare Equipment & Supplies
-2.71%
Key Executives
Chairman/Director
Paul Stuka
Chief Executive Officer/Director
Marvin Slosman
Vice Chairman/Director
Isaac Blech
Chief Financial Officer/Chief Administrative Officer/Treasurer/Secretary/IR Contact Officer
Craig Shore
Executive Vice President
Agustin Gago
Director
Thomas Kester
Director
Gary Roubin
Independent Director
Michael Berman
Independent Director
Campbell Rogers
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About NSPR
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.

Webull offers kinds of InspireMD Inc stock information, including AMEX:NSPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NSPR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NSPR stock methods without spending real money on the virtual paper trading platform.